AVXL – Anavex Life Sciences Corp.
Anavex Life Sciences Corp.AVXL
$2.54Name : Anavex Life Sciences Corp.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $235,386,272.00
EPSttm : -0.46
Anavex Life Sciences Corp.
$2.54
3.05%$0.08
AVXL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
21.42
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
-0.02
EPS Last/This Y
0.21
EPS This/Next Y
-0.22
Price
2.53
Target Price
20
Analyst Recom
1
Performance Q
-45.26
Upside
-335.4%
Beta
1.14
Ticker: AVXL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | AVXL | 3.25 | 0.09 | 0.00 | 55098 |
| 2026-05-12 | AVXL | 3.05 | 0.08 | 0.70 | 62284 |
| 2026-05-13 | AVXL | 3.1 | 0.08 | 0.09 | 62420 |
| 2026-05-14 | AVXL | 3.09 | 0.08 | 0.02 | 62652 |
| 2026-05-15 | AVXL | 2.92 | 0.08 | 0.33 | 62735 |
| 2026-05-18 | AVXL | 2.88 | 0.08 | 0.07 | 59834 |
| 2026-05-19 | AVXL | 2.67 | 0.08 | 0.45 | 60402 |
| 2026-05-20 | AVXL | 2.75 | 0.08 | 2.18 | 60504 |
| 2026-05-21 | AVXL | 2.7 | 0.08 | 11.55 | 60727 |
| 2026-05-22 | AVXL | 2.69 | 0.09 | 0.09 | 60807 |
| 2026-05-26 | AVXL | 2.72 | 0.09 | 3.76 | 60692 |
| 2026-05-27 | AVXL | 2.75 | 0.10 | 4.33 | 61094 |
| 2026-05-28 | AVXL | 2.95 | 0.10 | 0.59 | 61242 |
| 2026-05-29 | AVXL | 3.03 | 0.10 | 0.05 | 61487 |
| 2026-06-02 | AVXL | 2.79 | 0.10 | 0.10 | 61732 |
| 2026-06-03 | AVXL | 2.64 | 0.10 | 0.20 | 61936 |
| 2026-06-04 | AVXL | 2.82 | 0.09 | 0.01 | 61362 |
| 2026-06-05 | AVXL | 2.58 | 0.09 | 0.02 | 61615 |
| 2026-06-08 | AVXL | 2.62 | 0.09 | 0.04 | 61817 |
| 2026-06-09 | AVXL | 2.53 | 0.08 | 0.13 | 61548 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | AVXL | 3.24 | 42.3 | - | -0.33 |
| 2026-05-12 | AVXL | 3.05 | 42.3 | - | -0.33 |
| 2026-05-13 | AVXL | 3.09 | 42.3 | - | -0.33 |
| 2026-05-14 | AVXL | 3.08 | 42.3 | - | -0.33 |
| 2026-05-15 | AVXL | 2.91 | 42.3 | - | -0.33 |
| 2026-05-18 | AVXL | 2.88 | 42.3 | - | -0.33 |
| 2026-05-19 | AVXL | 2.67 | 42.3 | - | -0.33 |
| 2026-05-20 | AVXL | 2.75 | 42.3 | - | -0.33 |
| 2026-05-21 | AVXL | 2.70 | 42.3 | - | -0.33 |
| 2026-05-22 | AVXL | 2.69 | 42.3 | - | -0.33 |
| 2026-05-26 | AVXL | 2.72 | 42.3 | - | -0.33 |
| 2026-05-27 | AVXL | 2.74 | 42.3 | - | -0.33 |
| 2026-05-28 | AVXL | 2.95 | 42.3 | - | -0.33 |
| 2026-05-29 | AVXL | 3.04 | 42.3 | - | -0.33 |
| 2026-06-01 | AVXL | 2.99 | 46.2 | - | -0.33 |
| 2026-06-02 | AVXL | 2.79 | 46.2 | - | -0.33 |
| 2026-06-03 | AVXL | 2.64 | 46.2 | - | -0.33 |
| 2026-06-04 | AVXL | 2.82 | 46.2 | - | -0.33 |
| 2026-06-05 | AVXL | 2.58 | 46.2 | - | -0.33 |
| 2026-06-08 | AVXL | 2.62 | 46.2 | - | -0.33 |
| 2026-06-09 | AVXL | 2.53 | 46.2 | - | -0.33 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | AVXL | 0.00 | 5.07 | 21.11 |
| 2026-05-12 | AVXL | 0.00 | 5.07 | 21.18 |
| 2026-05-13 | AVXL | 0.00 | 5.07 | 21.18 |
| 2026-05-14 | AVXL | 0.00 | 5.07 | 21.18 |
| 2026-05-15 | AVXL | 0.00 | 5.07 | 21.18 |
| 2026-05-18 | AVXL | 0.00 | 4.21 | 21.18 |
| 2026-05-19 | AVXL | 0.00 | 4.21 | 21.18 |
| 2026-05-20 | AVXL | 0.00 | 4.21 | 21.18 |
| 2026-05-21 | AVXL | 0.00 | 4.21 | 21.18 |
| 2026-05-22 | AVXL | 0.00 | 4.21 | 21.18 |
| 2026-05-26 | AVXL | 0.00 | 2.39 | 21.18 |
| 2026-05-27 | AVXL | 0.00 | 2.39 | 21.18 |
| 2026-05-28 | AVXL | 0.00 | 2.39 | 21.42 |
| 2026-05-29 | AVXL | 0.00 | 2.39 | 21.42 |
| 2026-06-02 | AVXL | 0.00 | 1.55 | 21.42 |
| 2026-06-03 | AVXL | 0.00 | 1.55 | 21.42 |
| 2026-06-04 | AVXL | 0.00 | 1.55 | 21.42 |
| 2026-06-05 | AVXL | 0.00 | 1.55 | 21.42 |
| 2026-06-08 | AVXL | 0.00 | 1.56 | 21.42 |
| 2026-06-09 | AVXL | 0.00 | 1.56 | 21.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.08
Insider Transactions
Institutional Transactions
1.56
Beta
1.14
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
18
Sentiment Score
1
Actual DrawDown %
92
Max Drawdown 5-Year %
-91.1
Target Price
20
P/E
Forward P/E
PEG
P/S
P/B
1.86
P/Free Cash Flow
EPS
-0.46
Average EPS Est. Cur. Y
-0.33
EPS Next Y. (Est.)
-0.55
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.64
Return on Equity vs Sector %
-59
Return on Equity vs Industry %
-42.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
AVXL
Healthcare
$2.54
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
36.9
Range 1M
6.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
38.9%
EPS NY
-66.7%
52W%
0.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+687.4% upside
Upside
+687.4%
Quality
10
Anavex Life Sciences Corp.Sector: Healthcare
Industry: Biotechnology
Employees: 34
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
AVXL
Latest News
—
Caricamento notizie per AVXL…
stock quote shares AVXL – Anavex Life Sciences Corp. Stock Price stock today
news today AVXL – Anavex Life Sciences Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch AVXL – Anavex Life Sciences Corp. yahoo finance google finance
stock history AVXL – Anavex Life Sciences Corp. invest stock market
stock prices AVXL premarket after hours
ticker AVXL fair value insiders trading